Description
Caberos 0.125 mg Driada Medical — cabergoline from Driada Medical at 0.125 mg. Selective D2 dopamine agonist suppressing pituitary prolactin. Manages prolactin elevation from nandrolone or trenbolone cycles.
Key Benefits
- Dopamine D2 agonist — suppresses prolactin
- On-cycle support for nandrolone and trenbolone users
- Low-dose protocol 0.25 mg twice weekly
- Pull prolactin at week 6 to confirm dose adequacy
- Mood elevation and libido support are bonuses
- Each unit dosed at 0.125 mg — see Recommended Dosage below for protocol-specific intake
How It Works
Ergot-derived dopamine D2 receptor agonist. Suppresses pituitary prolactin secretion. Clinically used for hyperprolactinemia and Parkinson’s. In AAS protocols: counters the prolactin rise from progestagenic compounds (19-nors).
Pharmacokinetics
Plasma half-life approximately 63–69 hours. Twice-weekly dosing sufficient. Steady-state in 2 weeks.
Potential Side Effects
Nausea common initially — take with food. Orthostatic hypotension possible. High-dose long-term use carries cardiac valve concern (documented in Parkinson’s patients on 3+ mg/day — not at AAS-protocol doses).
Cycle & Stacking Guide
On-cycle support with nandrolone, trenbolone, or progestagenic orals (oxymetholone). 0.25 mg 2×/week throughout cycle. Bloodwork at week 6 — target prolactin <15 ng/mL.
Manufacturer Notes
Driada Medical positions itself at the affordable end of the market while maintaining third-party lab verification. Their vial caps carry a tamper-seal date code; batch COAs available through the distributor.
Storage & Handling
Store at recommended temperature (15–25°C; peptides and HGH at 2–8°C after reconstitution). Protect from light and moisture. Keep out of reach of children. For research and educational purposes only.
Reviews
There are no reviews yet.